Apellis Pharmaceuticals Inc (1JK.SG)
Stuttgart - Stuttgart Delayed Price. Currency in EUR
Add to watchlist
At close: 08:02AM CEST
| Previous Close | 38.97 |
| Open | 39.21 |
| Bid | 39.15 x N/A |
| Ask | 39.34 x N/A |
| Day's Range | 39.21 - 39.21 |
| 52 Week Range | 18.70 - 87.00 |
| Volume | |
| Avg. Volume | 31 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Simply Wall St.
Analysts Are Updating Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates After Its First-Quarter Results
There's been a notable change in appetite for Apellis Pharmaceuticals, Inc. ( NASDAQ:APLS ) shares in the week since...
- Insider Monkey
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q1 2024 Earnings Call Transcript May 7, 2024 Apellis Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.54 EPS, expectations were $-0.54. Apellis Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good […]
- Simply Wall St.
Apellis Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Apellis Pharmaceuticals ( NASDAQ:APLS ) First Quarter 2024 Results Key Financial Results Revenue: US$172.3m (up 284...
© 2024 Yahoo. All rights reserved.